We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » UCB Snags Fourth Cimzia Indication; Fifth Proposed Indication is Rejected
UCB Snags Fourth Cimzia Indication; Fifth Proposed Indication is Rejected
October 25, 2013
The FDA granted UCB a fourth U.S. indication for its arthritis drug Cimzia as a treatment for active ankylosing spondylitis (AS).